| Travere Therapeutics, Inc.

Retrophin Announces Divestment of Non-Core Assets to Turing Pharmaceuticals

Read more about Retrophin Announces Divestment of Non-Core Assets to Turing Pharmaceuticals

Retrophin Announces Appointment of Jeffrey A. Meckler to Board of Directors

Read more about Retrophin Announces Appointment of Jeffrey A. Meckler to Board of Directors

Retrophin Announces Appointment of Gary Lyons to Board of Directors

Read more about Retrophin Announces Appointment of Gary Lyons to Board of Directors

Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more about Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrophin Announces Leadership Reorganization

Read more about Retrophin Announces Leadership Reorganization

Retrophin Announces Changes to Board of Directors and Management Team

Read more about Retrophin Announces Changes to Board of Directors and Management Team

Retrophin Reports Second Quarter 2014 Financial Results

Read more about Retrophin Reports Second Quarter 2014 Financial Results

Retrophin to Report Second Quarter 2014 Financial Results

Read more about Retrophin to Report Second Quarter 2014 Financial Results

Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals

Read more about Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals

Ligand Licenses DARA Program to Retrophin

Read more about Ligand Licenses DARA Program to Retrophin

Download Library